A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis. (PubMed, Int J Mol Sci) - Sep 27, 2026 - "Pirfenidone and nintedanib slow lung function decline, and the PDE4B inhibitor nerandomilast and treprostinil have recently shown promise as next-generation treatments. In conclusion, nintedanib retained robust antifibrotic activity when administered via dietary supplementation despite lower, but continuous, active plasma concentrations. Collectively, these findings indicate that optimizing drug delivery and absorption kinetics may achieve sustained therapeutic efficacy while reducing unnecessary exposure to supratherapeutic concentrations, thereby potentially improving tolerability."
Biomarker • Clinical • Journal • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • FGF2 • MMP7
|
|
Alice Pappani; Antonella Maria Nogara; Costanza Anna Maria Lagrasta; Federico Quaini; Francesca Ruscitti; Giancarlo Aquino; Marcello Trevisani; Maria Gloria Pittelli; Mariarosaria Barrea; Paola Caruso; Paolo Spagnolo; Roberta Volta; Silvia Pontis; Vanessa Pitozzi
|